米那普仑治疗纤维肌痛症的研究进展  

Research progress of milnacipran in treatment of fibromyalgia

作　　者：杜秋燕 蒋常莲 刘莉[1] 叶兰仙[1] Du Qiuyan;Jiang Changlian;Liu Li;Ye Lanxian(Department of Mental Health,Lanzhou University Second Hospital,Lanzhou 730030,China)

机构地区：[1]兰州大学第二医院心理卫生科,730030

出　　处：《中国医药》2021年第5期792-795,共4页China Medicine

基　　金：甘肃省中医药管理局科研课题(GZK-2017-52)。

摘　　要：纤维肌痛症也称纤维肌痛综合征,因其广泛的症状学特征和极高的共病率已成为一种高度致残疾病,临床误诊率高,患者极易伴发抑郁情绪而导致病情加重,目前其发病机制尚不明确。米那普仑是一种特异性5-羟色胺和去甲肾上腺素再摄取抑制剂,能同等强度地抑制神经末梢对5-羟色胺和去甲肾上腺素的再摄取,临床上主要用于抑郁症及纤维肌痛症的治疗。本文对米那普仑治疗纤维肌痛症的可能机制、临床效果及安全性等进行综述,以期为米那普仑在纤维肌痛症中的应用提供参考。Fibromyalgia,also known as fibromyalgia syndrome,has become a highly disabling disease due to its extensive symptomatic characteristics and high rate of comorbidities.The misdiagnosis rate is high,and it is easy to be accompanied by depression,which leads to exacerbation of the condition.At present,the pathogenesis is not clear.Milnacipran is a specific serotonin and norepinephrine reuptake inhibitor,which can inhibit the reuptake of serotonin and norepinephrine by nerve endings with equal intensity.It is mainly used in the clinical treatment of depression and fibromyalgia.This article reviews the possible mechanism,clinical efficacy and safety of milnacipran in the treatment of fibromyalgia,in order to provide reference for the more scientific application of milnacipran in fibromyalgia.

关 键 词：纤维肌痛症 米那普仑 研究进展 

分 类 号：R441.1[医药卫生—诊断学]